Contrasting Profusa (PFSA) and Its Peers

Profusa (NASDAQ:PFSA) is one of 29 public companies in the “Surgical, Medical, And Dental Instruments And Supplies” industry, but how does it contrast to its rivals? We will compare Profusa to similar businesses based on the strength of its profitability, risk, valuation, analyst recommendations, dividends, earnings and institutional ownership.

Profitability

This table compares Profusa and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Profusa	N/A	N/A	-880.32%
Profusa Competitors	-672.41%	-133.75%	-59.01%

Volatility & Risk

Profusa has a beta of -0.14, meaning that its stock price is 114% less volatile than the S&P 500. Comparatively, Profusa’s rivals have a beta of 1.76, meaning that their average stock price is 76% more volatile than the S&P 500.

Institutional and Insider Ownership

9.8% of Profusa shares are owned by institutional investors. Comparatively, 22.5% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are owned by institutional investors. 11.4% of Profusa shares are owned by insiders. Comparatively, 18.1% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Profusa and its rivals revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Profusa	N/A	-$8.71 million	-0.01
Profusa Competitors	$59.54 million	-$32.15 million	4.45

Profusa’s rivals have higher revenue, but lower earnings than Profusa. Profusa is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Profusa and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profusa	1	0	0	0	1.00
Profusa Competitors	77	78	159	6	2.29

As a group, “Surgical, Medical, And Dental Instruments And Supplies” companies have a potential upside of 39.85%. Given Profusa’s rivals stronger consensus rating and higher possible upside, analysts clearly believe Profusa has less favorable growth aspects than its rivals.

Summary

Profusa rivals beat Profusa on 10 of the 13 factors compared.

About Profusa

NorthView Acquisition Corporation does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It also intends to focus its search on businesses that are focused on healthcare sector. The company was incorporated in 2021 and is based in New York, New York. NorthView Acquisition Corporation is a subsidiary of NorthView Sponsor I, LLC.